Azenta Life Science, headquartered in the United States, is a leading provider in the life sciences industry, specialising in sample management and genomic services. Founded in 2021, the company has quickly established itself as a key player, offering innovative solutions that streamline research and development processes for biopharmaceutical and academic institutions. With a focus on biobanking, sample logistics, and genomic analysis, Azenta Life Science distinguishes itself through its advanced technology and commitment to quality. The company’s core services include automated sample storage, data management, and comprehensive genomic services, all designed to enhance efficiency and accuracy in scientific research. Recognised for its robust market position, Azenta Life Science continues to achieve significant milestones, contributing to advancements in personalised medicine and drug discovery. Its dedication to innovation and customer satisfaction solidifies its reputation as a trusted partner in the life sciences sector.
How does Azenta Life Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Azenta Life Science's score of 48 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Azenta Life Sciences reported total greenhouse gas emissions of approximately 4,147,000 kg CO2e for Scope 1 and about 9,989,000 kg CO2e for Scope 2, resulting in a combined total of around 14,136,000 kg CO2e. This marks a decrease from 2023, where emissions were approximately 4,513,000 kg CO2e for Scope 1 and about 10,565,000 kg CO2e for Scope 2, totalling around 15,078,000 kg CO2e. The company has set ambitious targets to reduce its emissions, committing to a 55% reduction in Scope 1 and Scope 2 greenhouse gas emissions by 2033, using 2022 as the baseline year. This commitment aligns with their long-term goal of achieving net-zero emissions across all scopes by 2050. Azenta's emissions reduction strategy reflects a proactive approach to climate change, focusing on both immediate and long-term sustainability goals within the pharmaceuticals and biotechnology sector.
Access structured emissions data, company-specific emission factors, and source documents
2022 | 2023 | 2024 | |
---|---|---|---|
Scope 1 | 4,647,000 | 0,000,000 | 0,000,000 |
Scope 2 | 13,492,000 | 00,000,000 | 0,000,000 |
Scope 3 | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Azenta Life Science is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.